Toshiba America Medical Systems is planning a full-court pressat this month's Radiological Society of North America meeting.In an effort to secure a greater U.S. market share, the Japanesevendor is introducing a range of new products, many of which
Toshiba America Medical Systems is planning a full-court pressat this month's Radiological Society of North America meeting.In an effort to secure a greater U.S. market share, the Japanesevendor is introducing a range of new products, many of which havebeen designed with input from U.S. clinicians, according to RaviSharma, vice president of marketing.
At the top of Toshiba's list of product introductions is Flexart,a new 0.5-tesla MRI scanner to be shown as a works-in-progress.Flexart uses a helium-only superconducting magnet designed forlow cryogen boil-off and low maintenance. The system is activelyshielded to reduce eddy currents and can be sited in a space assmall as 45 square meters, Sharma said.
"This has been developed mainly for community hospitalsand hospitals that are going to see high growth in the managed-careenvironment," he said.
Flexart will be priced at about $1 million and will be positionedas Toshiba's premium mid-field offering. The company will continueto sell MRT-50A, its existing mid-field product.
In CT, Toshiba will unveil Xpress/SX, an upgrade to the vendor'sXpress slip-ring CT scanner. The upgrade will add solid-statedetectors to Xpress, which enable faster helical scanning andimproved image quality, Sharma said.
The system is powered by a 48-kW generator with an output of400 mAs and runs a 3.5-million heat unit x-ray tube. Xpress/SXhas Food and Drug Administration marketing clearance. It willbe priced at about $1 million, Sharma said.
Other new product introductions include:
FDA Grants Fast Track Designation to Emerging Agent for Brain PET Imaging
June 11th 2025Currently being evaluated in a phase 2b clinical trial, the 18F-RAD101 PET imaging agent garnered the FDA’s fast track designation for distinguishing between recurrent disease and treatment impact for brain metastases derived from solid tumors.
New PSMA PET Prep Product Now Available in the U.S.
June 11th 2025Offering an extended shelf life, the FDA-approved Gozellix, a preparation kit for gallium-68 (68Ga) gozetotide injection, is indicated for use in PSMA PET imaging of prostate cancer patients with suspected recurrence or metastasis.